By vgreene, 11 March, 2015 Annually review the need for continued osteoporosis meds; assess adherence, diet/supplements,<sup>53,54</sup> exercise,55 fall prevention,<sup>56,57</sup> etc
By vgreene, 11 March, 2015 Arrange follow-up at least annually; √ biochemical markers<sup>52</sup> if planning to monitor tx effects
By vgreene, 11 March, 2015 Bisphosphonate (alendronate, ibandronate, risedronate, zoledronic acid), calcitonin, estrogen agonist/antagonist (raloxifene), estrogens, tissue-selective estrogen complex (conjugated estrogen/bazedoxifene), PTH (1-34) (teriparatide), RANKLi (denosumab)
By vgreene, 11 March, 2015 Consider FDA-approved drug on case-by-case basis, in light of pt preference, if:
By vgreene, 11 March, 2015 T-score −1.0 to −2.5<sup>48</sup> (osteopenia) @ femoral neck/total hip/L-spine: if 10-yr hip fx probability ≥3%, or 10-yr major osteoporosis-related fx probability ≥20% per FRAX<sup>49</sup>